Unhealthy diet concept: A large pile of white sugar cubes next to generic red soda cans representing high calorie and sugar content in soft drinks

(Credit: © FERNANDO stock.adobe.com)

In a Nutshell

  • A lab study tested 39 sweeteners against 25 gut bacteria and found that three-quarters of the sweeteners affected the growth of at least one strain.
  • Pairing sweeteners with commonly consumed compounds produced more than 100 previously unreported interactions between the compounds and gut bacteria.
  • The stevia-derived sweetener isosteviol plus the antidepressant duloxetine together suppressed two bacteria tied to gut health, more than either did alone.

Millions of Americans take antidepressants every day. Millions more reach for diet sodas, sugar-free gum, or low-calorie snacks sweetened with natural and artificial sweeteners. What happens when both of those things meet in the gut at the same time? According to a new study, the answer may be more tangled than previously thought.

Researchers tested 39 commercially available sweeteners, the kind found in everything from soft drinks and candy to cereal and baby formula, against 25 gut bacterial strains and species to see how they interact. Reporting in Molecular Systems Biology, the team found that three-quarters of the sweeteners directly affected the growth of at least one bacterial strain. A bigger surprise came when sweeteners were combined with other commonly ingested compounds, including the widely prescribed antidepressant duloxetine. Those combinations produced more than 100 previously unreported interactions, some of which appeared to harm bacteria closely linked to human health.

Conducted entirely in a laboratory setting, the study does not prove that the same effects occur in a living human body. But the scale of the screening and the depth of the follow-up analysis make it one of the most thorough looks yet at what low-calorie sweeteners might be doing to the microscopic community living in the human digestive system.

How a Sweetener and an Antidepressant Gang Up on Gut Bacteria

Of all the findings in the study, one combination stood out. Isosteviol, a compound derived from the stevia plant and used as a sweetener ingredient, combined with duloxetine, the antidepressant sold under the brand name Cymbalta, to suppress two types of bacteria that scientists associate with a healthy gut, hitting one of them especially hard.

One of those bacteria, Roseburia intestinalis, has been linked to blood sugar regulation and protection against intestinal inflammation. The other, Parabacteroides merdae, is a common gut resident tied to a healthy microbial community. When isosteviol and duloxetine were present together, their combined suppressive effect on these bacteria was greater than what either compound caused on its own.

Duloxetine is no niche medication. In 2022 and 2023, it ranked as the 31st-most-prescribed drug in the United States, with more than 18 million prescriptions filled and more than 4 million patients taking it, according to data cited in the study. Given how widely stevia-derived sweeteners are used in food products, many people may routinely consume both.

How Scientists Tested 39 Sweeteners Against Gut Bacteria

Based at the MRC Toxicology Unit at the University of Cambridge and the European Molecular Biology Laboratory in Heidelberg, Germany, the research team built their experiment around 25 gut bacterial strains and species chosen to represent the broad range of bacteria found in a healthy human gut: friendly probiotic species, common residents, and some opportunistic troublemakers.

Against these bacteria, the team screened all 39 sweeteners they could obtain in pure form, covering both natural options like stevia compounds and monk fruit extract and synthetic ones like saccharin, aspartame, and sucralose. Every sweetener was tested individually against every bacterial strain, producing 975 unique pairings. Interactions counted as real only if they held up across multiple independent experiments and multiple concentrations, a strict standard that filtered out false positives.

For the combination testing, the researchers screened the same 39 sweeteners alongside four compounds commonly consumed with sweeteners: advantame (another sweetener increasingly used in processed foods), caffeine, vanillin (a flavor compound found in everything from cakes to baby formula), and duloxetine. That expanded the analysis to 3,900 three-way interactions between sweeteners, bacteria, and the added compounds.

In total, the combination screen identified 102 significant interactions involving nine gut bacterial species. Most of them, 68 out of 102, were cases where one compound softened the impact of the other. But 34 were cases where the combination hit harder than either compound alone. The strongest of all the compounds involved is isosteviol, followed by duloxetine, acting on Roseburia intestinalis.

Infographic illustrating the laboratory workflow researchers used to test 39 sweeteners, 25 gut bacterial strains, and four common compounds, resulting in 102 significant sweetener-compound interactions.
Infographic by StudyFinds

Beyond Slowed Growth: Effects on Gut Bacteria and Human Cells

Finding that a sweetener and an antidepressant can together suppress specific gut bacteria would be notable on its own. The researchers went further, building a miniature artificial gut community comprising all 25 bacterial strains and exposing it to the isosteviol-duloxetine combination over several growth cycles to observe how the community changed under pressure.

Combined treatment caused a significant drop in overall species diversity. Of the 25 bacteria, 24 grew less in isolation after exposure to both compounds together.

To understand what was happening at a molecular level, the team analyzed changes in proteins made by Roseburia intestinalis and Parabacteroides merdae after exposure. The compounds appeared to interfere with the bacteria’s ability to manage what moves in and out of the cell, specifically disrupting proteins that carry small molecules across the outer membrane. A separate genetic analysis using a library of bacterial mutants identified the same membrane transport proteins as key determinants of bacterial survival of the isosteviol-duloxetine combination.

One of the more arresting downstream results involved the spent liquid from the bacterial community, essentially the chemical output that bacteria produce and release. Applied to human cells in a dish, fluid from communities treated with the isosteviol-duloxetine combination was significantly more toxic to HeLa cells than fluid from untreated communities. Researchers ruled out the compounds themselves as the direct cause; the altered bacterial output appeared to drive the effect.

When Caco-2 cells, a human cell line modeled on the lining of the colon, were exposed to the same bacterial fluid, secretion of two immune signaling proteins, interleukin-6 and interleukin-8, fell by more than 75% compared with fluid from untreated communities. These proteins are part of the gut’s immune defense. Their suppression could, depending on the context, indicate a weakened ability to fight off pathogens, though the researchers note that the significance would depend on a person’s individual health.

Bacteria exposed to the combination also produced different amounts of butyric acid, a compound tied to anti-inflammatory effects, improved insulin sensitivity, and protection against diet-related obesity, and one that gut cells burn for energy. In Roseburia intestinalis, butyric acid dropped by more than 25% after co-exposure. These are the kinds of bacterial outputs that researchers link to broader human health.

A Starting Point, Not a Final Answer

Study authors are clear that this work was done in laboratory conditions, not in living humans, and that the concentrations and combinations tested represent only a sliver of what people actually consume. The synthetic bacterial community, while carefully built, is far simpler than the microbial world in a real human gut. Interactions observed in isolated bacterial cultures do not always translate to community settings, and the fact that gut bacteria differ from person to person adds another layer of uncertainty.

Even so, the breadth of the screening, nearly 4,000 three-way interactions systematically tested with strict validation and follow-up molecular analysis, makes clear that the combination of sweeteners and common drugs deserves serious scientific attention. Duloxetine is taken by millions of people who also, in all likelihood, consume sweetened food and drinks. Isosteviol appears in products marketed as natural and healthy alternatives to sugar.

Gut bacteria are increasingly understood to be central to metabolic health, immune function, and even mental health. A study that identifies more than 100 previously unknown interactions among what people eat, the medicines they take, and the bacteria in their digestive systems is not a reason for panic. It is a reason to look much more closely.

Disclaimer: This article summarizes findings from a laboratory study conducted on bacterial cultures and human cell lines, not on living people. The results do not establish that consuming these sweeteners and medications together causes harm in the human body, and they should not be taken as medical advice. Anyone with questions about their medications or diet should consult a licensed healthcare provider before making changes.


Paper Notes

Study Limitations

Researchers conducted the entire study in vitro, meaning in laboratory conditions using bacterial cultures and cell lines rather than living humans or animals. All sweeteners and co-consumed compounds were tested at a single concentration of 50 micromoles per liter, which the authors estimated to be within the range relevant for the colon on average but which cannot capture the full range of real-world exposures or individual variation. The synthetic bacterial community used in community-level experiments contained 25 strains, far less diverse than the actual human gut microbiome. Authors acknowledge that the choice of growth medium can influence outcomes and may limit the breadth of the findings’ applicability. They also note that only four co-consumed compounds were used in the main combination screen, a limited slice of what people actually ingest alongside sweeteners. Trophic interactions, such as bacteria feeding on one another’s byproducts, can change species responses in community settings in ways that differ from single-culture results. The authors state that future in vivo studies are needed to confirm these findings in living systems.

Funding and Disclosures

According to the paper, this project received funding from the European Union’s Horizon 2020 research and innovation programme (grant numbers 866028 and 814408) and from the UK Medical Research Council (project number MC_UU_00025/11). The authors declare no competing interests.

Publication Details

Authors: Sonja Blasche, Vinita Periwal, Nonantzin Beristain Covarrubias, Anna E. Lindell, Indra Roux, Stephan Kamrad, Simone Mozzachiodi, Rob Bradley, Hilal Ozgur, Bini Ramachandran, Vladimir Benes, and Kiran Raosaheb Patil. Blasche and Periwal contributed equally as co-first authors. Affiliations include the MRC Toxicology Unit, University of Cambridge, Cambridge, UK, and the European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.

Journal: Molecular Systems Biology
Paper Title: “Common xenobiotics modulate gut microbial responses to low-calorie sweeteners in vitro”
DOI: 10.1038/s44320-026-00225-6
Received: April 11, 2025; Revised: May 13, 2026; Accepted: June 9, 2026

About StudyFinds Analysis

Called "brilliant," "fantastic," and "spot on" by scientists and researchers, our acclaimed StudyFinds Analysis articles are created using an exclusive AI-based model with complete human oversight by the StudyFinds Editorial Team. For these articles, we use an unparalleled LLM process across multiple systems to analyze entire journal papers, extract data, and create accurate, accessible content. Our writing and editing team proofreads and polishes each and every article before publishing. With recent studies showing that artificial intelligence can interpret scientific research as well as (or even better) than field experts and specialists, StudyFinds was among the earliest to adopt and test this technology before approving its widespread use on our site. We stand by our practice and continuously update our processes to ensure the very highest level of accuracy. Read our AI Policy (link below) for more information.

Our Editorial Process

StudyFinds publishes digestible, agenda-free, transparent research summaries that are intended to inform the reader as well as stir civil, educated debate. We do not agree nor disagree with any of the studies we post, rather, we encourage our readers to debate the veracity of the findings themselves. All articles published on StudyFinds are vetted by our editors prior to publication and include links back to the source or corresponding journal article, if possible.

Our Editorial Team

Steve Fink

Editor-in-Chief

John Anderer

Associate Editor

Leave a Comment